Compare HLP & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HLP | ACOG |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.2M | 193.6M |
| IPO Year | 2021 | 2024 |
| Metric | HLP | ACOG |
|---|---|---|
| Price | $2.53 | $9.15 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 115.6K | 98.1K |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,220,275.00 |
| Revenue This Year | N/A | $153.87 |
| Revenue Next Year | N/A | $85.66 |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $4.50 |
| 52 Week High | $2.63 | $10.14 |
| Indicator | HLP | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 76.03 | 50.32 |
| Support Level | $0.78 | $7.50 |
| Resistance Level | N/A | $9.17 |
| Average True Range (ATR) | 0.17 | 0.48 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 79.37 | 55.75 |
Hongli Group Inc is an offshore holding company. Through its subsidiaries, it is engaged in the cold-rolled steel profile manufacturing in China. Its main business operation focuses on the design, production, deep processing, and sales of custom-made profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation industries. The group operates in a single segment, which manufactures and sells agricultural machinery cab assemblies, construction machinery cab assemblies, excavator cab assemblies, and special-shaped steel pipes. It generates the majority of its reveneue from PRC.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.